Iterum Therapeutics PLC
NASDAQ:ITRM

Watchlist Manager
Iterum Therapeutics PLC Logo
Iterum Therapeutics PLC
NASDAQ:ITRM
Watchlist
Price: 1.81 USD 2.26% Market Closed
Market Cap: 41.1m USD
Have any thoughts about
Iterum Therapeutics PLC?
Write Note

Iterum Therapeutics PLC
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Iterum Therapeutics PLC
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Iterum Therapeutics PLC
NASDAQ:ITRM
Other Liabilities
$16k
CAGR 3-Years
-84%
CAGR 5-Years
-71%
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Other Liabilities
$660.3m
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
9%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Other Liabilities
$182.1m
CAGR 3-Years
-6%
CAGR 5-Years
-7%
CAGR 10-Years
17%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Other Liabilities
$40.8m
CAGR 3-Years
96%
CAGR 5-Years
6%
CAGR 10-Years
17%
G
GH Research PLC
NASDAQ:GHRS
Other Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cosmo Pharmaceuticals NV
SIX:COPN
Other Liabilities
€766k
CAGR 3-Years
-35%
CAGR 5-Years
-27%
CAGR 10-Years
4%
No Stocks Found

Iterum Therapeutics PLC
Glance View

Market Cap
41.1m USD
Industry
Pharmaceuticals

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.

ITRM Intrinsic Value
Not Available

See Also

What is Iterum Therapeutics PLC's Other Liabilities?
Other Liabilities
16k USD

Based on the financial report for Jun 30, 2024, Iterum Therapeutics PLC's Other Liabilities amounts to 16k USD.

What is Iterum Therapeutics PLC's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
-71%

Over the last year, the Other Liabilities growth was -99%. The average annual Other Liabilities growth rates for Iterum Therapeutics PLC have been -84% over the past three years , -71% over the past five years .

Back to Top